Top

Published in:

01-06-2012 | Original article

Expression of antigen processing and presenting molecules in brain metastasis of breast cancer

Authors: Yan Liu, Yoshihiro Komohara, Natalie Domenick, Masasuke Ohno, Maki Ikeura, Ronald L. Hamilton, Craig Horbinski, Xinhui Wang, Soldano Ferrone, Hideho Okada

Published in: Cancer Immunology, Immunotherapy | Issue 6/2012

Abstract

Defects in human leukocyte antigen class I antigen processing machinery (APM) component expression can have a negative impact on the clinical course of tumors and the response to T cell-based immunotherapy. Since brain metastases of breast cancer are of increasing clinical significance, the APM component expression levels and CD8⁺ T cell infiltration patterns were analyzed in primary breast and metastatic brain lesions of breast cancer by immunohistochemistry. Comparison of unpaired 50 primary and 33 brain metastases showed lower expression of β2-microglobulin, transporter associated with antigen processing (TAP) 1, TAP2 and calnexin in the brain lesions. Although no significant differences were found in APM component scores between primary breast and brain lesions in 15 paired cases, primary breast lesions of which patients eventually developed brain metastases showed lower levels of β2-microglobulin, TAP1 and calnexin compared with breast lesions without known brain metastases. The extent of CD8⁺ T cell infiltration was significantly higher in the lesions without metastasis compared with the ones with brain metastases, and was positively associated with the expression of TAP1 and calnexin. Furthermore, mouse tumor cells stably transfected with silencing hairpin (sh)RNA for TAP1 demonstrated a decreased susceptibility to cytotoxic T lymphocytes in vitro and enhanced spontaneous brain metastasis in vivo. These data support the functional significance of TAP1 expression in tumor cells. Taken together, our data suggest that patients with low or defective TAP1 or calnexin in primary breast cancers may be at higher risks for developing brain metastasis due to the defects in T cell-based immunosurveillance.

Available only for authorised users

Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan detroit cancer surveillance system. J Clin Oncol 22(14):2865–2872. doi:10.1200/jco.2004.12.149 PubMedCrossRef

Patel RR, Mehta MP (2007) Targeted therapy for brain metastases: improving the therapeutic ratio. Clin Cancer Res 13(6):1675–1683. doi:10.1158/1078-0432.ccr-06-2489 PubMedCrossRef

Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS (2005) Breast cancer metastasis to the central nervous system. Am J Pathol 167(4):913–920PubMedCrossRef

Lin NU, Bellon JR, Winer EP (2004) CNS metastases in breast cancer. J Clin Oncol 22(17):3608–3617. doi:10.1200/jco.2004.01.175 PubMedCrossRef

Stemmler H-J, Heinemann V (2008) Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge. Oncologist 13(7):739–750. doi:10.1634/theoncologist.2008-0052 PubMedCrossRef

Kennecke H, Yerushalmi R, Woods R, Cheang MCU, Voduc D, Speers CH, Nielsen TO, Gelmon K (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28(20):3271–3277. doi:10.1200/jco.2009.25.9820 PubMedCrossRef

Martin JJ, Kondziolka D (2005) Indications for resection and radiosurgery for brain metastases. Curr Opin Oncol 17(6):584–587PubMedCrossRef

Kondziolka D, Kano H, Harrison GL, Yang H-C, Liew DN, Niranjan A, Brufsky AM, Flickinger JC, Lunsford LD (2010) Stereotactic radiosurgery as primary and salvage treatment for brain metastases from breast cancer. J Neurosurg. doi:10.3171/2010.8.JNS10461

Okada H, Kohanbash G, Zhu X, Kastenhuber ER, Hoji A, Ueda R, Fujita M (2009) Immunotherapeutic approaches for glioma. Crit Rev Immunol 29(1):1–42PubMed

10.

Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, Mintz AH, Engh JA, Bartlett DL, Brown CK, Zeh H, Holtzman MP, Reinhart TA, Whiteside TL, Butterfield LH, Hamilton RL, Potter DM, Pollack IF, Salazar AM, Lieberman FS (2011) Induction of CD8⁺ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with α-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 29(3):330–336. doi:10.1200/jco.2010.30.7744 PubMedCrossRef

11.

Campoli M, Ferrone S (2008) HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 27(45):5869–5885PubMedCrossRef

12.

Cabrera T, Maleno I, Collado A, Lopez Nevot MA, Tait BD, Garrido F (2007) Analysis of HLA class I alterations in tumors: choosing a strategy based on known patterns of underlying molecular mechanisms. Tissue Antigens 69:264–268. doi:10.1111/j.1399-0039.2006.00777.x PubMedCrossRef

13.

Cathro H, Smolkin M, Theodorescu D, Jo V, Ferrone S, Frierson H (2010) Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas. Cancer Immunol Immunother 59(3):465–472. doi:10.1007/s00262-009-0765-9 PubMedCrossRef

14.

Raffaghello L, Nozza P, Morandi F, Camoriano M, Wang X, Garre ML, Cama A, Basso G, Ferrone S, Gambini C, Pistoia V (2007) Expression and functional analysis of human leukocyte antigen class I antigen-processing machinery in medulloblastoma. Cancer Res 67(11):5471–5478. doi:10.1158/0008-5472.can-06-4735 PubMedCrossRef

15.

Vitale M, Rezzani R, Rodella L, Zauli G, Grigolato P, Cadei M, Hicklin DJ, Ferrone S (1998) HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res 58(4):737–742PubMed

16.

Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, Restifo NP (1998) gp100/pmel 17 is a murine tumor rejection antigen: induction of “self”-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 188(2):277–286. doi:10.1084/jem.188.2.277 PubMedCrossRef

17.

Stam N, Spits H, Ploegh H (1986) Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 137(7):2299–2306PubMed

18.

Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Dammacco F (2003) {beta}2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol 171(4):1918–1926PubMed

19.

Sernee MF, Ploegh HL, Schust DJ (1998) Why certain antibodies cross-react with HLA-A and HLA-G: epitope mapping of two common MHC class I reagents. Mol Immunol 35(3):177–188PubMedCrossRef

20.

Maio M, Altomonte M, Tatake R, Zeff RA, Ferrone S (1991) Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene. J Clin Investig 88(1):282–289PubMedCrossRef

21.

Bandoh N, Ogino T, Cho HS, Hur SY, Shen J, Wang X, Kato S, Miyokawa N, Harabuchi Y, Ferrone S (2005) Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies. Tissue Antigens 66(3):185–194. doi:10.1111/j.1399-0039.2005.00462.x PubMedCrossRef

22.

Wang X, Campoli M, Cho HS, Ogino T, Bandoh N, Shen J, Hur SY, Kageshita T, Ferrone S (2005) A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections. J Immunol Methods 299(1–2):139–151PubMedCrossRef

23.

Ogino T, Wang X, Kato S, Miyokawa N, Harabuchi Y, Ferrone S (2003) Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow cytometry and immunohistochemical staining. Tissue Antigens 62:385–393. doi:10.1034/j.1399-0039.2003.00114.x PubMedCrossRef

24.

Fujita M, Zhu X, Sasaki K, Ueda R, Low KL, Pollack IF, Okada H (2008) Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma. J Immunol 180(4):2089–2098PubMed

25.

Racanelli V, Leone P, Frassanito MA, Brunetti C, Perosa F, Ferrone S, Dammacco F (2010) Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8⁺ T cells and characterize the progression of MGUS to multiple myeloma. Blood 115(6):1185–1193. doi:10.1182/blood-2009-06-228676 PubMedCrossRef

26.

Zhai Y, Yang JC, Spiess P, Nishimura MI, Overwijk WW, Roberts B, Restifo NP, Rosenberg SA (1997) Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J Immunother 20(1):15–25PubMedCrossRef

27.

le Doussal V, Tubiana-Hulin M, Hacene K, Friedman S, Brunet M (1989) Nuclear characteristics as indicators of prognosis in node negative breast cancer patients. Breast Cancer Res Treat 14(2):207–216. doi:10.1007/bf01810737 PubMedCrossRef

28.

Atkins D, Breuckmann A, Schmahl GE, Binner P, Ferrone S, Krummenauer F, Störkel S, Seliger B (2004) MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. Int J Cancer 109(2):265–273. doi:10.1002/ijc.11681 PubMedCrossRef

29.

Bandoh N, Ogino T, Katayama A, Takahara M, Katada A, Hayashi T, Harabuchi Y (2010) HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis. Oncol Rep 23(4):933–939PubMedCrossRef

30.

Kloetzel P-M (2004) The proteasome and MHC class I antigen processing. Biochimica et Biophysica Acta (BBA) Mol Cell Res 1695(1–3):225–233CrossRef

31.

Hansen TH, Bouvier M (2009) MHC class I antigen presentation: learning from viral evasion strategies. Nat Rev Immunol 9(7):503–513PubMedCrossRef

32.

Seliger B (2008) Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol Immunother 57(11):1719–1726. doi:10.1007/s00262-008-0515-4 PubMedCrossRef

33.

Mehling M, Simon P, Mittelbronn M, Meyermann R, Ferrone S, Weller M, Wiendl H (2007) WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism? Acta Neuropathol 114(2):111–119. doi:10.1007/s00401-007-0231-8 PubMedCrossRef

34.

Lopez-Albaitero A, Nayak JV, Ogino T, Machandia A, Gooding W, DeLeo AB, Ferrone S, Ferris RL (2006) Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol 176(6):3402–3409PubMed

35.

Lou Y, Vitalis TZ, Basha G, Cai B, Chen SS, Choi KB, Jeffries AP, Elliott WM, Atkins D, Seliger B, Jefferies WA (2005) Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specific immune responses and survival. Cancer Res 65(17):7926–7933. doi:10.1158/0008-5472.can-04-3977 PubMed

36.

Lou Y, Basha G, Seipp RP, Cai B, Chen SS, Moise AR, Jeffries AP, Gopaul RS, Vitalis TZ, Jefferies WA (2008) Combining the antigen processing components TAP and tapasin elicits enhanced tumor-free survival. Clin Cancer Res 14(5):1494–1501. doi:10.1158/1078-0432.ccr-07-1066 PubMedCrossRef

37.

Sarrabayrouse G, Corvaisier M, Ouisse L-H, Bossard C, Mével BL, Potiron L, Meurette G, Gervois N, Jotereau F (2011) Tumor-reactive CD4⁺CD8αβ⁺ CD103⁺ αβT cells: a prevalent tumor-reactive T-cell subset in metastatic colorectal cancers. Int J Cancer 128(12):2923–2932. doi:10.1002/ijc.25640 PubMedCrossRef

38.

Han LY, Fletcher MS, Urbauer DL, Mueller P, Landen CN, Kamat AA, Lin YG, Merritt WM, Spannuth WA, Deavers MT, De Geest K, Gershenson DM, Lutgendorf SK, Ferrone S, Sood AK (2008) HLA class I antigen processing machinery component expression and intratumoral T-cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res 14(11):3372–3379. doi:10.1158/1078-0432.ccr-07-4433 PubMedCrossRef

39.

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795):1960–1964PubMedCrossRef

40.

Yang I, Tihan T, Han SJ, Wrensch MR, Wiencke J, Sughrue ME, Parsa AT (2010) CD8⁺ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival. J Clin Neurosci 17(11):1381–1385PubMedCrossRef

41.

Lohr J, Ratliff T, Huppertz A, Ge Y, Dictus C, Ahmadi R, Grau S, Hiraoka N, Eckstein V, Ecker RC, Korff T, von Deimling A, Unterberg A, Beckhove P, Herold-Mende C (2011) Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-beta. Clin Cancer Res 17(13):4296–4308. doi:10.1158/1078-0432.CCR-10-2557 PubMedCrossRef

42.

He H, Somlo G, Yun Y, Chu PG (2009) Dendritic cell infiltration in lymph node positive breast carcinomas. Breast J 15(2):218–220. doi:10.1111/j.1524-4741.2009.00707.x PubMedCrossRef

43.

Mansfield A, Heikkila P, von Smitten K, Vakkila J, Leidenius M (2011) Metastasis to sentinel lymph nodes in breast cancer is associated with maturation arrest of dendritic cells and poor co-localization of dendritic cells and CD8⁺ T cells. Virchows Arch 459(4):391–398. doi:10.1007/s00428-011-1145-3 CrossRef

44.

Zhang J, Patel L, Pienta KJ (2010) CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev 21(1):41–48. doi:10.1016/j.cytogfr.2009.11.009 PubMedCrossRef

45.

Mantovani A, Savino B, Locati M, Zammataro L, Allavena P, Bonecchi R (2010) The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev 21(1):27–39. doi:10.1016/j.cytogfr.2009.11.007 PubMedCrossRef

46.

Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc P-H, Trajanoski Z, Fridman W-H, Galon J (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353(25):2654–2666. doi:10.1056/NEJMoa051424 PubMedCrossRef

47.

Lott ST, Chen N, Chandler DS, Yang Q, Wang L, Rodriguez M, Xie H, Balasenthil S, Buchholz TA, Sahin AA, Chaung K, Zhang B, Olufemi S-E, Chen J, Adams H, Band V, El-Naggar AK, Frazier ML, Keyomarsi K, Hunt KK, Sen S, Haffty B, Hewitt SM, Krahe R, Killary AM (2009) DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer. PLoS Med 6(5):e1000068PubMedCrossRef

48.

Varga D, Koenig J, Kuhr K, Strunz K, Geyer V, Kurzeder C, Atassi Z, Blettner M, Kreienberg R, Woeckel A (2010) Comparison of early onset breast cancer patients to older premenopausal breast cancer patients. Arch Gynecol Obstet 282(4):427–432. doi:10.1007/s00404-009-1339-y PubMedCrossRef

49.

Bauer K, Parise C, Caggiano V (2010) Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer. BMC Cancer 10(1):228PubMedCrossRef

50.

Van Belle V, Van Calster B, Brouckaert O, Vanden Bempt I, Pintens S, Harvey V, Murray P, Naume B, Wiedswang G, Paridaens R, Moerman P, Amant F, Leunen K, Smeets A, Drijkoningen M, Wildiers H, Christiaens M-R, Vergote I, Van Huffel S, Neven P (2010) Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis. J Clin Oncol 28(27):4129–4134. doi:10.1200/jco.2009.26.4200 PubMedCrossRef

51.

Dunnwald L, Rossing M, Li C (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 9(1):R6PubMedCrossRef

52.

Sari E, Guler G, Hayran M, Gullu I, Altundag K, Ozisik Y (2011) Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer. Med Oncol 28(1):57–63. doi:10.1007/s12032-010-9418-2 CrossRef

53.

Gong Y, Han EY, Guo M, Pusztai L, Sneige N (2011) Stability of estrogen receptor status in breast carcinoma. Cancer 117(4):705–713. doi:10.1002/cncr.25506 PubMedCrossRef

54.

Herrmann F, Lehr H-A, Drexler I, Sutter G, Hengstler J, Wollscheid U, Seliger B (2004) HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res 64(1):215–220. doi:10.1158/0008-5472.can-2522-2 PubMedCrossRef

55.

Mimura K, Ando T, Poschke I, Mougiakakos D, Johansson CC, Ichikawa J, Okita R, Nishimura MI, Handke D, Krug N, Choudhury A, Seliger B, Kiessling R (2011) T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2. Int J Cancer 128(2):390–401. doi:10.1002/ijc.25613 PubMedCrossRef

Title: Expression of antigen processing and presenting molecules in brain metastasis of breast cancer
Authors: Yan Liu
Yoshihiro Komohara
Natalie Domenick
Masasuke Ohno
Maki Ikeura
Ronald L. Hamilton
Craig Horbinski
Xinhui Wang
Soldano Ferrone
Hideho Okada
Publication date: 01-06-2012
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 6/2012
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-011-1137-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2012

Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria

Myeloid-derived suppressor cells impair the quality of dendritic cell vaccines

Calreticulin as a potential diagnostic biomarker for lung cancer

CAF05: cationic liposomes that incorporate synthetic cord factor and poly(I:C) induce CTL immunity and reduce tumor burden in mice

Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen

Reflections upon human cancer immune responsiveness to T cell-based therapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer